Amr S Abu Lila

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1142190/publications.pdf

Version: 2024-02-01

99	3,207	172386	175177
papers	citations	29 h-index	52 g-index

102	102	102	3694
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage. Journal of Controlled Release, 2013, 172, 38-47.	4.8	502
2	PEGylated liposomes: immunological responses. Science and Technology of Advanced Materials, 2019, 20, 710-724.	2.8	287
3	Liposomal Delivery Systems: Design Optimization and Current Applications. Biological and Pharmaceutical Bulletin, 2017, 40, 1-10.	0.6	271
4	Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. Journal of Controlled Release, 2009, 137, 8-14.	4.8	101
5	Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. International Journal of Pharmaceutics, 2013, 456, 235-242.	2.6	90
6	Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes. Pharmaceutical Research, 2010, 27, 1171-1183.	1.7	81
7	Synthesis of Gold Nanoparticles by Using Green Machinery: Characterization and In Vitro Toxicity. Nanomaterials, 2021, 11, 808.	1.9	66
8	A Double-modulation Strategy in Cancer Treatment With a Chemotherapeutic Agent and siRNA. Molecular Therapy, 2011, 19, 2040-2047.	3.7	61
9	Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. Journal of Controlled Release, 2010, 142, 167-173.	4.8	55
10	A Novel Strategy to Increase the Yield of Exosomes (Extracellular Vesicles) for an Expansion of Basic Research. Biological and Pharmaceutical Bulletin, 2018, 41, 733-742.	0.6	54
11	A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 142-149.	2.0	53
12	Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. Journal of Controlled Release, 2009, 134, 18-25.	4.8	50
13	Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer. Drug Delivery, 2021, 28, 1626-1636.	2.5	49
14	Relationship between the Concentration of Anti-polyethylene Glycol (PEG) Immunoglobulin M (IgM) and the Intensity of the Accelerated Blood Clearance (ABC) Phenomenon against PEGylated Liposomes in Mice. Biological and Pharmaceutical Bulletin, 2015, 38, 417-424.	0.6	46
15	Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 145, 27-34.	2.0	44
16	Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity. Journal of Controlled Release, 2017, 250, 20-26.	4.8	43
17	Therapeutic Applications of Biostable Silver Nanoparticles Synthesized Using Peel Extract of Benincasa hispida: Antibacterial and Anticancer Activities. Nanomaterials, 2020, 10, 1954.	1.9	40
18	Preparation, characterization and evaluation of anti-inflammatory and anti-nociceptive effects of brucine-loaded nanoemulgel. Colloids and Surfaces B: Biointerfaces, 2021, 205, 111868.	2.5	40

#	Article	IF	Citations
19	Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Toxicology and Applied Pharmacology, 2014, 277, 30-38.	1.3	37
20	Application of Polyglycerol Coating to Plasmid DNA Lipoplex for the Evasion of the Accelerated Blood Clearance Phenomenon in Nucleic Acid Delivery. Journal of Pharmaceutical Sciences, 2014, 103, 557-566.	1.6	36
21	Pulmonary Targeting of Inhalable Moxifloxacin Microspheres for Effective Management of Tuberculosis. Pharmaceutics, 2021, 13, 79.	2.0	36
22	Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: A possible mechanism and the potential for clinical application. International Journal of Pharmaceutics, 2012, 438, 176-183.	2.6	35
23	Alteration of Salmonella enterica Virulence and Host Pathogenesis through Targeting sdiA by Using the CRISPR-Cas9 System. Microorganisms, 2021, 9, 2564.	1.6	35
24	Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: Promise for clinical application. International Journal of Pharmaceutics, 2013, 441, 395-401.	2.6	34
25	Efficacy of SPG-ODN 1826 Nanovehicles in Inducing M1 Phenotype through TLR-9 Activation in Murine Alveolar J774A.1 Cells: Plausible Nano-Immunotherapy for Lung Carcinoma. International Journal of Molecular Sciences, 2021, 22, 6833.	1.8	33
26	Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon. Journal of Controlled Release, 2020, 323, 102-109.	4.8	32
27	Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice. Journal of Controlled Release, 2021, 334, 327-334.	4.8	32
28	Not Only Antimicrobial: Metronidazole Mitigates the Virulence of Proteus mirabilis Isolated from Macerated Diabetic Foot Ulcer. Applied Sciences (Switzerland), 2021, 11, 6847.	1.3	32
29	Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opinion on Drug Delivery, 2009, 6, 1297-1309.	2.4	31
30	Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways. Scientific Reports, 2018, 8, 14493.	1.6	31
31	Anti-diabetics and antimicrobials: Harmony of mutual interplay. World Journal of Diabetes, 2021, 12, 1832-1855.	1.3	31
32	Secnidazole Is a Promising Imidazole Mitigator of Serratia marcescens Virulence. Microorganisms, 2021, 9, 2333.	1.6	30
33	Elevated Levels of IL-33, IL-17 and IL-25 Indicate the Progression from Chronicity to Hepatocellular Carcinoma in Hepatitis C Virus Patients. Pathogens, 2022, 11, 57.	1.2	30
34	Selective Delivery of Oxaliplatin to Tumor Tissue by Nanocarrier System Enhances Overall Therapeutic Efficacy of the Encapsulated Oxaliplatin. Biological and Pharmaceutical Bulletin, 2014, 37, 206-211.	0.6	29
35	Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed. Journal of Controlled Release, 2015, 220, 29-36.	4.8	29
36	Cefotaxime Mediated Synthesis of Gold Nanoparticles: Characterization and Antibacterial Activity. Polymers, 2022, 14, 771.	2.0	27

#	Article	IF	Citations
37	A Novel Platform for Cancer Vaccines: Antigen-Selective Delivery to Splenic Marginal Zone B Cells via Repeated Injections of PEGylated Liposomes. Journal of Immunology, 2018, 201, 2969-2976.	0.4	25
38	<i>Ex-Vivo</i>/<i>in-Vitro</i> Anti-polyethylene Glycol (PEG) Immunoglobulin M Production from Murine Splenic B Cells Stimulated by PEGylated Liposome. Biological and Pharmaceutical Bulletin, 2013, 36, 1842-1848.	0.6	24
39	B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice. Journal of Controlled Release, 2014, 184, 1-8.	4.8	23
40	Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model. Cancer Science, 2017, 108, 1864-1869.	1.7	21
41	Enhanced Cytotoxic Activity of Docetaxel-Loaded Silk Fibroin Nanoparticles against Breast Cancer Cells. Polymers, 2021, 13, 1416.	2.0	21
42	Quality by Design for Optimizing a Novel Liposomal Jojoba Oil-Based Emulgel to Ameliorate the Anti-Inflammatory Effect of Brucine. Gels, 2021, 7, 219.	2.1	21
43	Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 142-151.	2.0	20
44	Brucine-Loaded Ethosomal Gel: Design, Optimization, and Anti-inflammatory Activity. AAPS PharmSciTech, 2021, 22, 269.	1.5	20
45	Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 56-62.	2.0	19
46	Fast disintegrating tablet of Valsartan for the treatment of pediatric hypertension: In vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology, 2018, 43, 194-200.	1.4	18
47	Enhancement of Vancomycin Potential against Pathogenic Bacterial Strains via Gold Nano-Formulations: A Nano-Antibiotic Approach. Materials, 2022, 15, 1108.	1.3	18
48	Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production. Gene Therapy, 2014, 21, 593-598.	2.3	17
49	Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model. International Journal of Oncology, 2016, 48, 1399-1407.	1.4	17
50	Complement activation induced by PEG enhances humoral immune responses against antigens encapsulated in PEG-modified liposomes. Journal of Controlled Release, 2021, 329, 1046-1053.	4.8	17
51	The Co-Delivery of Oxaliplatin Abrogates the Immunogenic Response to PEGylated siRNA-Lipoplex. Pharmaceutical Research, 2013, 30, 2344-2354.	1.7	16
52	Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model. European Journal of Pharmaceutical Sciences, 2016, 81, 60-66.	1.9	16
53	A Cell Assay for Detecting Anti-PEG Immune Response against PEG-Modified Therapeutics. Pharmaceutical Research, 2018, 35, 223.	1.7	16
54	Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose. Journal of Controlled Release, 2015, 220, 406-413.	4.8	15

#	Article	IF	Citations
55	Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 524-531.	2.0	14
56	Preparation and characterization of intravaginal vardenafil suppositories targeting a complementary treatment to boost in vitro fertilization process. European Journal of Pharmaceutical Sciences, 2018, 111, 113-120.	1.9	14
57	Phytosomes as a Plausible Nano-Delivery System for Enhanced Oral Bioavailability and Improved Hepatoprotective Activity of Silymarin. Pharmaceuticals, 2022, 15, 790.	1.7	14
58	Anti-PEG IgM Production via a PEGylated Nano-Carrier System for Nucleic Acid Delivery. , 2013, 948, 35-47.		13
59	Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry. Molecular Pharmaceutics, 2018, 15, 403-409.	2.3	13
60	Doxorubicin Expands <i>in Vivo</i> Secretion of Circulating Exosome in Mice. Biological and Pharmaceutical Bulletin, 2018, 41, 1078-1083.	0.6	13
61	Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice. Molecular Pharmaceutics, 2020, 17, 2964-2970.	2.3	13
62	Experimental Design and Optimization of Nano-Transfersomal Gel to Enhance the Hypoglycemic Activity of Silymarin. Polymers, 2022, 14, 508.	2.0	13
63	Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing. International Journal of Nanomedicine, 2016, Volume 11, 5573-5582.	3.3	12
64	Metronomic chemotherapy and nanocarrier platforms. Cancer Letters, 2017, 400, 232-242.	3.2	12
65	Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens. Journal of Controlled Release, 2018, 270, 114-119.	4.8	12
66	Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy. Molecular Pharmaceutics, 2016, 13, 3955-3963.	2.3	11
67	Tamoxifen-loaded functionalized graphene nanoribbons for breast cancer therapy. Journal of Drug Delivery Science and Technology, 2021, 63, 102499.	1.4	11
68	Design, in vitro/in vivo evaluation of meclizine HCl-loaded floating microspheres targeting pregnancy-related nausea and vomiting. Journal of Drug Delivery Science and Technology, 2018, 47, 395-403.	1.4	10
69	Ghatti gum-base graft copolymer: a plausible platform for pH-controlled delivery of antidiabetic drugs. RSC Advances, 2021, 11, 14871-14882.	1.7	10
70	Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM <i>via</i> a T Cell-Dependent Mechanism. Biological and Pharmaceutical Bulletin, 2020, 43, 1393-1397.	0.6	10
71	Formulation, Development and Evaluation of Ibuprofen Loaded Nano-transferosomal Gel for the Treatment of Psoriasis. Journal of Pharmaceutical Research International, 0, , 1-8.	1.0	10
72	PEGylation and anti-PEG antibodies. , 2018, , 51-68.		9

#	Article	IF	Citations
73	Anti-PEG IgM Production via a PEGylated Nanocarrier System for Nucleic Acid Delivery. Methods in Molecular Biology, 2019, 1943, 333-346.	0.4	9
74	Revitalizing the local anesthetic effect of Mebeverine hydrochloride via encapsulation within ethosomal vesicular system. Colloids and Surfaces B: Biointerfaces, 2020, 194, 111208.	2.5	9
75	Screening of Apoptosis Pathway-Mediated Anti-Proliferative Activity of the Phytochemical Compound Furanodienone against Human Non-Small Lung Cancer A-549 Cells. Life, 2022, 12, 114.	1.1	9
76	Development and Evaluation of Clove and Cinnamon Supercritical Fluid Extracts-Loaded Emulgel for Antifungal Activity in Denture Stomatitis. Gels, 2022, 8, 33.	2.1	8
77	Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: Synergy or antagonism?. International Journal of Pharmaceutics, 2012, 426, 263-270.	2.6	7
78	Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model. Cancer Letters, 2017, 400, 223-231.	3.2	7
79	Modulation of Drug Release from Natural Polymer Matrices by Response Surface Methodology: in vitro and in vivo Evaluation . Drug Design, Development and Therapy, 2020, Volume 14, 5325-5336.	2.0	7
80	Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model. Drug Delivery and Translational Research, 2012, 2, 77-86.	3.0	6
81	Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules. Journal of Controlled Release, 2017, 255, 210-217.	4.8	5
82	A simplified method for manufacturing RNAi therapeutics for local administration. International Journal of Pharmaceutics, 2019, 564, 256-262.	2.6	5
83	Immunological responses to PEGylated proteins. , 2020, , 103-123.		5
84	Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (DoxilÂ®) in C26 Tumor-Bearing Immunocompetent Mice. Pharmaceutics, 2020, 12, 990.	2.0	5
85	A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma. Molecules, 2020, 25, 1725.	1.7	5
86	Doxorubicin Embedded into Nanofibrillated Bacterial Cellulose (NFBC) Produces a Promising Therapeutic Outcome for Peritoneally Metastatic Gastric Cancer in Mice Models via Intraperitoneal Direct Injection. Nanomaterials, 2021, 11, 1697.	1.9	5
87	Folic acid-conjugated raloxifene-loaded graphene-based nanocarrier: Fabrication, characterization and antitumor screening. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2021, 625, 126971.	2.3	5
88	A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes. International Journal of Pharmaceutics, 2022, 615, 121539.	2.6	5
89	Poly Îµ-Caprolactone Nanoparticles for Sustained Intra-Articular Immune Modulation in Adjuvant-Induced Arthritis Rodent Model. Pharmaceutics, 2022, 14, 519.	2.0	5
90	Preparation and Characterization of a Novel Mucoadhesive Carvedilol Nanosponge: A Promising Platform for Buccal Anti-Hypertensive Delivery. Gels, 2022, 8, 235.	2.1	5

#	Article	IF	Citations
91	Treatment of pulmonary arterial hypertension by vardenafil-solid dispersion lozenges as a potential alternative drug delivery system. Journal of Drug Delivery Science and Technology, 2020, 55, 101444.	1.4	4
92	I.p.-injected cationic liposomes are retained and accumulate in peritoneally disseminated tumors. Journal of Controlled Release, 2022, 341, 524-532.	4.8	4
93	Inflammation targeted nanomedicines: Patents and applications in cancer therapy. Seminars in Cancer Biology, 2022, 86, 645-663.	4.3	4
94	Design, synthesis and cytotoxic evaluation of 2-amino-4- aryl-6-substituted pyridine-3,5-dicarbonitrile derivatives. Tropical Journal of Pharmaceutical Research, 2021, 20, 2127-2133.	0.2	3
95	Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation. Pharmaceuticals, 2022, 15, 560.	1.7	3
96	Liposomal Nanomedicines. Frontiers in Nanobiomedical Research, 2014, , 1-53.	0.1	2
97	Development and optimization of dual drug-loaded nanoparticles for the potent anticancer effect on renal carcinoma. Journal of Drug Delivery Science and Technology, 2020, 59, 101846.	1.4	2
98	Mebeverine Hydrochloride Loaded Chitosan Microspheres as Potential Treatment Targeting Irritable Bowel Syndrome: Box-Behnken Design Optimization. International Journal of Pharmaceutical Investigation, 2020, 10, 326-331.	0.2	2
99	Immune Response to PEGylated Nanomedicines: Impact of IgM Response. Biological and Medical Physics Series, 2018, , 371-388.	0.3	0